Carbon Tax / CBAM

The pharmaceutical industry carries a moderate-high social and labor structural risk, primarily due to vulnerabilities within its complex global supply chains. While direct manufacturing operations in developed economies generally adhere to high occupational health and safety standards, a substantial portion of raw materials and Active Pharmaceutical Ingredients (APIs) are sourced from regions with less robust labor laws. This exposure increases risks of excessive working hours, unsafe conditions, and inadequate wages in lower-tier supplier facilities.

• Supply Chain Risk: Reports indicate that API manufacturing in countries like India and China faces challenges with labor rights and safety compliance, contributing to global supply chain risk (Business & Human Rights Resource Centre, 2022).
• Regulatory Disparity: Differences in labor law enforcement across global supply chains create a structural disparity in worker protection, impacting the overall industry's social footprint (International Labour Organization, 2021).

The pharmaceutical industry operates under a moderate-high structural regulatory density, marked by pervasive oversight from development to market. Agencies such as the FDA and EMA impose rigorous standards for R&D (GLP), clinical trials (GCP), manufacturing (GMP), and post-market surveillance.

• Oversight: Each stage requires extensive documentation, audits, and multi-year approval processes, exemplified by New Drug Applications (NDAs) spanning thousands of pages.
• Compliance Cost: Regulatory compliance can represent 10-20% of total R&D costs, reflecting deeply embedded and continuous oversight.

The pharmaceutical industry has achieved a moderate-low level of traceability fragmentation for finished products in major markets through item-level serialization mandates. Regulations like the US Drug Supply Chain Security Act (DSCSA), fully effective in November 2023, and the EU Falsified Medicines Directive (FMD), effective since 2019, require unique identifiers for each saleable unit.

• Metric: These directives cover over 80% of the global pharmaceutical market by revenue.
• Impact: While significantly improving anti-counterfeiting efforts and patient safety for finished goods, challenges remain in achieving full global interoperability and granular, real-time traceability for all raw materials across the entire supply chain.